BioCentury
ARTICLE | Company News

uniQure grants Chiesi commercialization rights to gene therapies

July 10, 2013 12:15 AM UTC

uniQure B.V. (Amsterdam, the Netherlands) granted Chiesi Farmaceutici S.p.A. (Parma, Italy) exclusive rights to commercialize Glybera alipogene tiparvovec and co-develop and commercialize AMT-060 in Europe, Brazil, Mexico, Pakistan, Turkey and the Commonwealth of Independent States (CIS). Chiesi also received commercialization rights to Glybera in China. Glybera is approved in the EU to treat lipoprotein lipase (LPL) deficiency in patients with recurring, acute pancreatitis; the partners plan to launch Glybera in the EU in 1H14. AMT-060 is in development to treat hemophilia B (see BioCentury, July 30, 2012). ...